![]() Client Work Sharp Therapeutics Corp Announces Completion of Qualifying TransactionDecember 20, 2024 Authors Marshall EidingerPartner Dominique CarliAssociate Geoffrey (Geoff) DavisAssociate Jonathan BergAssociate Joseph N. BlinickPartner William A. BortolinAssociate Sharp Therapeutics Corp. (Sharp Therapeutics), formerly EVP Capital Inc. (EVP Capital), an Ontario corporation is pleased to announce the successful completion of its qualifying transaction by way of a reverse takeover of Sharp Edge Labs, Inc. (Sharp Edge). Pursuant to a statutory plan of arrangement under the Business Corporations Act (Ontario), EVP Capital acquired all the issued and outstanding common stock in the capital of Sharp Edge in exchange for common shares of the resulting issuer, Sharp Therapeutics. Sharp Therapeutics will begin trading on the TSXV under the symbol "SHRX" in late December 2024. Bennett Jones acted for Sharp Edge Labs, Inc. The Bennett Jones team was led by Marshall Eidinger (Securities and M&A) and includes Dominique Carli, Geoff Davis, Tatiana Henkenhaf, Jonathan Berg (Securities and M&A), James Morand (Tax), Joseph Blinick and Will Bortolin (Litigation). Republishing Requests For permission to republish this or any other publication, contact Amrita Kochhar at kochhara@bennettjones.com. For informational purposes only This publication provides an overview of legal trends and updates for informational purposes only. For personalized legal advice, please contact the authors. AuthorsMarshall Eidinger, Partner Toronto • 416.777.5389 • eidingerm@bennettjones.com Dominique Carli, Associate Toronto • 416.777.4657 • carlid@bennettjones.com Geoffrey (Geoff) Davis, Associate Toronto • 416.777.7823 • davisg@bennettjones.com Jonathan Berg, Associate Toronto • 416.777.7862 • bergj@bennettjones.com Joseph N. Blinick, Partner Toronto • 416.777.4828 • blinickj@bennettjones.com William A. Bortolin, Associate Toronto • 416.777.6126 • bortolinw@bennettjones.com |